Vermillion, Inc. (Nasdaq: VRML) to Ring The Nasdaq Stock Market Closing Bell

ADVISORY, Aug. 31, 2016 --

What: 

Vermillion, Inc. (Nasdaq:VRML), a bio-analytical solutions company focused on gynecologic disease, will visit the Nasdaq MarketSite in Times Square, to help kick off Ovarian Cancer Awareness Month. 

In honor of the occasion, Valerie Palmieri, President and Chief Executive Officer, will ring the Closing Bell along with OVA1 Blood Test Spokespersons:

• Shannon Miller- America’s Most Decorated Olympic Gymnast & Ovarian Cancer survivor
• Sherry Pollex- Life partner of NASCAR Driver Martin Truex, Jr. and Ovarian Cancer Survivor

Where: 
Nasdaq MarketSite – 4 Times Square – 43^rd & Broadway – Broadcast Studio

When: 
Thursday, September 1, 2016 – 3:45 p.m. to 4:00 p.m. ET          

Vermillion Contact: 
Katie Leighton
(610) 513-6930 
[email protected]

Nasdaq MarketSite: 
Emily Pan
(646) 441-5120 
[email protected]

Feed Information: 
Fiber Line (Encompass Waterfront): 4463

Gal 3C/06C 95.05 degrees West
18 mhz Lower
DL 3811 Vertical
FEC 3/4
SR 13.235
DR 18.295411
MOD 4:2:0
DVBS QPSK

Social Media: 
For multimedia features such as exclusive content, photo postings, status updates and video of bell ceremonies, please visit our Facebook page: 
http://www.facebook.com/NASDAQ.

For photos from ceremonies and events, please visit our Instagram page: 
http://instagram.com/nasdaq

For livestream of ceremonies and events, please visit our YouTube page: 
http://www.youtube.com/nasdaq/live

For news tweets, please visit our Twitter page: 
http://twitter.com/nasdaq

For exciting viral content and ceremony photos, please visit our Tumblr page: 
http://nasdaq.tumblr.com/

Webcast:
A live stream of the Nasdaq Closing Bell will be available at:
https://new.livestream.com/nasdaq/live or http://www.nasdaq.com/about/marketsitetowervideo.asx

Photos:
To obtain a hi-resolution photograph of the Market Close, please go to http://business.nasdaq.com/discover/market-bell-ceremonies and click on the market close of your choice.

About Vermillion 
Vermillion, Inc. is dedicated to the discovery, development and commercialization of novel high-value diagnostic and bio-analytical solutions that help physicians diagnose, treat and improve gynecologic health outcomes for women. Vermillion, along with its prestigious scientific collaborators, discovers, develops, and delivers innovative diagnostic and technology tools that help women with serious diseases. The company’s initial in vitro diagnostic test, OVA1®, was the first FDA-cleared, protein-based In Vitro Diagnostic Multivariate Index Assay, and represented a new class of software-based liquid biopsy in vitro diagnostics. In March 2016, Vermillion received FDA clearance for Overa™, a second generation OVA1 test with significantly improved specificity and ease of use. For additional information, including published clinical trials, visit www.vermillion.com.

About Nasdaq 
Nasdaq (Nasdaq:NDAQ) is a leading provider of trading, clearing, exchange technology, listing, information and public company services across six continents. Through its diverse portfolio of solutions, Nasdaq enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today's global capital markets. As the creator of the world's first electronic stock market, its technology powers more than 70 marketplaces in 50 countries, and 1 in 10 of the world's securities transactions. Nasdaq is home to more than 3,700 listed companies with a market value of approximately $9.3 trillion and nearly 18,000 corporate clients. To learn more, visit: nasdaq.com/ambition or business.nasdaq.com.

-NDAQA-